Mitochondria are sensors for HIV drugs

Trends in Pharmacological Sciences

Volumn 26, Issue 5, 2005, Pages 258-264

  Petit, Frédéric ^a   Fromenty, Bernard ^b   Owen, Andrew ^c   Estaquier, Jérôme ^a  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACADIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

APOPTOSIS; BIOSENSOR; BONE MARROW SUPPRESSION; CELL DEATH; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LONG TERM CARE; METABOLIC DISORDER; MITOCHONDRION; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SLEEP DISORDER;

EID: 18044388520     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.03.006     Document Type: Review

References (80)

1. F. Petit Intrinsic and extrinsic pathways signaling during HIV-1 mediated cell death Biochimie 85 2003 795 811
2. T. Imamichi Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors Curr. Pharm. Des. 10 2004 4039 4053
3. J. Fellay Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study Lancet 358 2001 1322 1327
4. W. Lewis Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions Antiviral Res. 58 2003 189 197
5. H. Lee Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase Biochemistry 42 2003 14711 14719
6. J.B. Alimonti Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS J. Gen. Virol. 84 2003 1649 1661
7. A.D. Badley Mechanisms of HIV-associated lymphocyte apoptosis Blood 96 2000 2951 2964
8. P. Andre An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses Proc. Natl. Acad. Sci. U. S. A. 95 1998 13120 13124
9. E.M. Sloand Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells Blood 96 2000 2735 2739
10. E.M. Sloand Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo Blood 94 1999 1021 1027
11. B.N. Phenix Decreased HIV-associated T cell apoptosis by HIV protease inhibitors AIDS Res. Hum. Retroviruses 16 2000 559 567
12. W. Lu, and J.M. Andrieu HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism Blood 96 2000 250 258
13. S. Chavan The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals Blood 98 2001 383 389
14. A. Macho Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers Blood 86 1995 2481 2487
15. H.C. Greenspan, and O.I. Aruoma Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activity Immunol. Today 15 1994 209 213
16. M. Carbonari Death of bystander cells by a novel pathway involving early mitochondrial damage in human immunodeficiency virus-related lymphadenopathy Blood 90 1997 209 216
17. D. Arnoult Mitochondria in HIV-1-induced apoptosis Biochem. Biophys. Res. Commun. 304 2003 561 574
18. B.N. Phenix Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss Blood 98 2001 1078 1085
19. E. Martinez Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults Lancet 364 2004 65 67
20. G. Moyle Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity Clin. Ther. 22 2000 911 936
21. O. Benveniste Possible mechanism of toxicity of zidovudine by induction of apoptosis of CD4+ and CD8+ T-cells in vivo Eur. J. Clin. Microbiol. Infect. Dis. 20 2001 896 897
22. M.C. Dalakas Mitochondrial myopathy caused by long-term zidovudine therapy New Engl. J. Med. 322 1990 1098 1105
23. L. Lamperth Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model Lab. Invest. 65 1991 742 751
24. G. Pezeshkpour Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies Hum. Pathol. 22 1991 1281 1288
25. W. Lewis Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts Lab. Invest. 65 1991 228 236
26. J.E. Groopman Zidovudine intolerance Rev. Infect. Dis. 12 Suppl. 5 1990 S500 S506
27. S.E. Lipshultz Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group New Engl. J. Med. 343 2000 759 766
28. R.E. Tuomala Antiretroviral therapy during pregnancy and the risk of an adverse outcome New Engl. J. Med. 346 2002 1863 1870
29. S. Blanche Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Lancet 354 1999 1084 1089
30. M.C. Poirier Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers J. Acquir. Immune Defic. Syndr. 33 2003 175 183
31. B. Barret Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort AIDS 17 2003 1769 1785
32. R.L. Divi Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir AIDS 18 2004 1013 1021
33. B. Shiramizu Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy J. Acquir. Immune Defic. Syndr. 32 2003 370 374
34. M. Gerschenson Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine AIDS Res. Hum. Retroviruses 20 2004 91 100
35. A.A. Pilon Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor Antimicrob. Agents Chemother. 46 2002 2687 2691
36. P. Domingo Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy AIDS 13 1999 2261 2267
37. A. Carr A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 1998 F51 F58
38. P. Dowell Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors J. Biol. Chem. 275 2000 41325 41332
39. J. Estaquier Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death J. Virol. 76 2002 5966 5973
40. P. Matarrese Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors J. Immunol. 170 2003 6006 6015
41. D.S. Zhong HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells Arterioscler. Thromb. Vasc. Biol. 22 2002 1560 1566
42. F. Pajonk The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells Cancer Res. 62 2002 5230 5235
43. S. Gaedicke Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis Cancer Res. 62 2002 6901 6908
44. R.P. van Heeswijk Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study AIDS 14 2000 F103 F110
45. A. Hsu Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers Antimicrob. Agents Chemother. 42 1998 2784 2791
46. B. Tan Multidrug resistance transporters and modulation Curr. Opin. Oncol. 12 2000 450 458
47. S.V. Ambudkar P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
48. K. Jones P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15 2001 1353 1358
49. J. Wijnholds Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs Proc. Natl. Acad. Sci. U. S. A. 97 2000 7476 7481
50. X. Wang Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein Biochem. Pharmacol. 68 2004 1363 1370
51. D.W. Haas MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study J. Acquir. Immune Defic. Syndr. 34 2003 295 298
52. M. Nasi MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients AIDS 17 2003 1696 1698
53. Z.L. Brumme Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response AIDS 17 2003 201 208
54. S. Chaillou Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir HIV Clin. Trials 3 2002 493 501
55. I. Ifergan Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians AIDS 16 2002 2340 2342
56. Owen, A. and Chandler, B. The implications of P-glycoprotein in HIV: friend or foe? Fundam. Clin. Pharmacol. (in press)
57. J. Wijnholds Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier J. Clin. Invest. 105 2000 279 285
58. B.J. Taylor Characterization of P-glycoprotein (Pgp) and multidrug resistance related protein (MRP) function in peripheral blood cells Cytometry 9 Suppl. 1998 60
59. A. Owen Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4 J. Virol. 78 2004 12022 12029
60. A. Owen Expression of PXR transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA Antivir. Ther. 9 2004 819 821
61. S.U. Sankatsing P glycoprotein in human immunodeficiency virus type 1 infection and therapy Antimicrob. Agents Chemother. 48 2004 1073 1081
62. J. Drewe HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833 Biochem. Pharmacol. 57 1999 1147 1152
63. B.A. Styrt Clinical toxicity of antiretroviral nucleoside analogs Antiviral Res. 31 1996 121 135
64. M. Viora Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs Int. J. Immunopharmacol. 19 1997 311 321
65. B. Fromenty The ins and outs of mitochondrial dysfunction in NASH Diabetes Metab. 30 2004 121 138
66. A.M. Tejera Chronic in vitro exposure to 3′-azido-2′, 3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells Breast Cancer Res. Treat. 65 2001 93 99
67. R.K. Lee Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas Cancer Res. 59 1999 5514 5520
68. G.M. Behrens Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy J. Clin. Invest. 110 2002 1319 1327
69. S.K. Gan Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy Diabetes 51 2002 3163 3169
70. M.G. Vander Heiden Growth factors can influence cell growth and survival through effects on glucose metabolism Mol. Cell. Biol. 21 2001 5899 5912
71. J.C. Rathmell In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability Mol. Cell 6 2000 683 692
72. M.M. Chi High insulin-like growth factor 1 (IGF-1) and insulin concentrations trigger apoptosis in the mouse blastocyst via down-regulation of the IGF-1 receptor Endocrinology 141 2000 4784 4792
73. A.D. Whetton Haemopoietic cell growth factor mediates cell survival via its action on glucose transport EMBO J. 3 1984 409 413
74. D.P. Brazil Advances in protein kinase B signalling: AKTion on multiple fronts Trends Biochem. Sci. 29 2004 233 242
75. A. Barthel Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1 J. Biol. Chem. 274 1999 20281 20286
76. A.D. Kohn Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation J. Biol. Chem. 271 1996 31372 31378
77. D.A. Cross Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789
78. L.A. Nolte The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle Diabetes 50 2001 1397 1401
79. A. Rudich Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues Diabetologia 46 2003 649 658
80. R. Ben-Romano Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors AIDS 17 2003 23 32